第二疗程罗莫索单抗在安慰剂或地舒单抗后的骨密度增益
这项2期剂量探索研究纳入低骨量绝经后女性,在初始罗莫索单抗或安慰剂后经安慰剂或地舒单抗治疗,再接受第二年罗莫索单抗。停药12个月后第二疗程罗莫索单抗再次带来快速大幅骨密度增益,地舒单抗后增益较小,安全性与第一疗程相似。
要点
- 停药12个月后第二疗程罗莫索单抗使腰椎骨密度增加12.4%,与初始治疗12.0%相似。
- 地舒单抗后第二疗程罗莫索单抗使腰椎骨密度增加2.3%,全髋维持不变。
- 第一与第二疗程罗莫索单抗安全性特征相似,未观察到新安全性发现。
核心结论
- 停药12个月后第二疗程罗莫索单抗再次带来快速大幅骨密度增益,地舒单抗后增益较小,未观察到新安全性发现。
研究设计与样本
- 2期剂量探索研究,低骨量绝经后女性(T值≤-2.0且≥-3.5)先接受罗莫索单抗或安慰剂(0-24月)后接受安慰剂或地舒单抗(24-36月),再接受1年罗莫索单抗(36-48月)。
- 进入36-48月期的167例参与者中,35例初始随机分配至罗莫索单抗210 mg每月。
主要发现
- 罗莫索单抗210 mg每月后安慰剂者,第二疗程罗莫索单抗(n=19)腰椎骨密度增加12.4%,初始治疗(0-12月)增加12.0%;全髋增加6.0% vs 5.5%。
- 地舒单抗后第二疗程罗莫索单抗(n=16)腰椎骨密度增加2.3%,全髋骨密度维持。
- 第一与第二疗程罗莫索单抗安全性特征相似。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Romosozumab is a therapy that stimulates bone formation and reduces bone resorption. In this study of postmenopausal women with low BMD, a second course of romosozumab following a period off treatment or on denosumab increased or maintained BMD, respectively, and was well tolerated, providing insight into treatment sequence options. INTRODUCTION: In patients with high fracture risk, therapies that stimulate bone formation provide rapid BMD gains; currently available agents, parathyroid hormone receptor agonists, are limited to a 2-year lifetime exposure and generally used for a single treatment course. However, for long-term osteoporosis management, a second treatment course may be appropriate. Romosozumab, a therapy with the dual effect of increasing bone formation and decreasing bone resorption, reduces fracture risk within 12 months. Here, we report efficacy and safety of a second romosozumab course. METHODS: In this phase 2, dose-finding study, postmenopausal women with low bone mass (T-score ≤ - 2.0 and ≥ - 3.5) received romosozumab or placebo (month 0-24) followed by placebo or denosumab (month 24-36); participants then received a year of romosozumab (month 36-48). RESULTS: Of 167 participants who entered the month 36-48 period, 35 had been initially randomized to romosozumab 210 mg monthly. In participants who received romosozumab 210 mg monthly followed by placebo, a second romosozumab course (n = 19) increased BMD by amounts similar to their initial treatment (month 0-12) at the lumbar spine (12.4%; 12.0%, respectively) and total hip (6.0%; 5.5%, respectively). Following denosumab, a second romosozumab course (n = 16) increased BMD at the lumbar spine (2.3%) and maintained BMD at the total hip. Safety profiles were similar between first and second romosozumab courses. CONCLUSIONS: After 12 months off-treatment, a second romosozumab course again led to rapid and large BMD gains. Following denosumab, BMD gains with romosozumab were smaller than with initial treatment. No new safety findings were observed during the second course.
引用
- Kendler DL, Bone HG, Massari F, et al. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos Int. 2019. PMID: 31628490. doi:10.1007/s00198-019-05146-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。